MediWound Ltd. (NASDAQ:MDWD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “

Several other research firms have also recently commented on MDWD. Wells Fargo & Co. initiated coverage on MediWound in a report on Wednesday, August 17th. They issued an “outperform” rating and a $14.00 price target for the company. Jefferies Group reduced their price objective on MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a report on Friday, July 29th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $13.63.

MediWound (NASDAQ:MDWD) opened at 7.57 on Wednesday. The stock’s 50 day moving average price is $7.70 and its 200-day moving average price is $7.79. MediWound has a 12-month low of $5.66 and a 12-month high of $10.47. The stock’s market capitalization is $165.40 million.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.11. The business earned $3.36 million during the quarter, compared to analyst estimates of $0.45 million. MediWound had a negative net margin of 2,332.07% and a negative return on equity of 103.14%. The firm’s quarterly revenue was up 115.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.19) earnings per share. Analysts expect that MediWound will post ($1.02) earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock worth $8,431,000 after buying an additional 100,723 shares during the period. Renaissance Technologies LLC boosted its position in MediWound by 19.4% in the first quarter. Renaissance Technologies LLC now owns 49,800 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 8,100 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new position in MediWound during the second quarter worth $13,302,000. Finally, United Services Automobile Association boosted its position in MediWound by 125.9% in the second quarter. United Services Automobile Association now owns 123,440 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 68,800 shares during the period. 26.48% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.

5 Day Chart for NASDAQ:MDWD

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with's FREE daily email newsletter.